VSTM - Verastem Oncology

-

$undefined

N/A

(N/A)

Verastem Oncology NASDAQ:VSTM Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition.

Location: 117 Kendrick St Ste 500, Massachusetts, 02494-2730, US | Website: www.verastem.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

339.6M

Cash

88.82M

Avg Qtr Burn

-26.19M

Short % of Float

23.19%

Insider Ownership

0.61%

Institutional Own.

65.93%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COPIKTRA (duvelisib) Details
Chronic lymphocytic leukemia, Small lymphocytic lymphoma , Cancer, Follicular lymphoma

Approved

Quarterly sales

Avutometinib (VS-6766) +/- Defactinib Details
Ovarian cancer, Cancer, Low-Grade Serous Ovarian Cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Avutometinib (VS-6766) + LUMAKRAS (sotorasib) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Initiation

Avutometinib(VS-6766) (RAF/MEK Inhibitor) Details
Non-small cell lung carcinoma, Cancer

Failed

Discontinued

Avutometinib (VS-6766) + KRAZATI (adagrasib) Details
Non-small cell lung carcinoma, Cancer

Failed

Discontinued